4,6-DIBROMO-1H-INDAZOLE-3-CARBOXYLIC ACID, 95%, 250mg

2-(3-Methoxyoxetan-3-yl)ethan-1-ol, 98%, 1g

4-Boc-2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine, 97.0%, 250mg

Methyl 2-bromo-4-fluorobenzoate, 95.0%, 500g

3-methoxy-5-(methoxycarbonyl)benzoic acid, 95.0%, 1g

4-Chloro-3H-[1,2,3]triazolo[4,5-c]pyridine, 95.0%, 5g

Benzyl 3-hydroxypropanoate, 95.0%, 250mg

(1R,3S,5R)-2-(tert-Butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid, 98%, 500mg

2,3-Dihydro-1H-pyrrolizine-7-carboxylic acid, 97%, 500mg

1-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1h-indol-1-yl]ethan-1-one, 95+%, 500mg

2,3,4,6,7,8-Hexahydro-1H-pyrimido[1,2-a]pyrimidine, 95.0%, 500g

2-(2,6-DICHLOROPHENYL)SUCCINIC ACID, 95.0%, 250mg

Capilar de punto de fusión, 80 mm, 1,55 mm, 1,15 mm, 1000 Unidad(es)